Telefon:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antikoerper-online.de

SARS-CoV-2 Spike S1 Antikörper (RBD) Primary Antibody

Reaktivität: SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) Crys, ELISA, Neut, SPR Wirt: Human Monoclonal CR3022
Pubmed (8)
Produktnummer ABIN6952546
$435.60
Zzgl. Versandkosten $45.00
200 μg
local_shipping Lieferung nach: Vereinigte Staaten von Amerika
Lieferung in 7 bis 11 Werktagen
  • Highlights
    • Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
    • Frequently used as reference in S-protein ELISAs and neutralization assays.
    • Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.
    Target
    Antikörpertyp
    Recombinant Antibody
    Bindungsspezifität
    RBD
    Reaktivität
    SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
    Wirt
    Human
    Klonalität
    Monoklonal
    Konjugat
    Dieser SARS-CoV-2 Spike S1 Antikörper ist unkonjugiert
    Applikation
    Crystallization (Crys), ELISA, Neutralization (Neut), Surface Plasmon Resonance (SPR)
    Verwendungszweck
    Recombinant monoclonal antibody CR3022 to SARS-CoV S Glycoprotein.
    Spezifität

    The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

    While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

    Kreuzreaktivität (Details)
    The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).
    Produktmerkmale
    The original monoclonal antibody (CR3022) was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
  • ABIN6952547 - Rabbit IgG
Aufreinigung
Protein A affinity purified
Immunogen
The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Klon
CR3022
Isotyp
IgG1 kappa
  • Applikationshinweise
    This antibody (CR3022) binds to both SARS-CoV and SARS-CoV-2 with high affinity. The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1 is available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).
    Kommentare

    The antibody clone CR3022 that is the basis for the recombinant SARS-CoV-2 Spike Subunit S1 RBD antibody ABIN6952546 was originally isolated from a convalescent SARS patient. This neutralizing antibody targets an epitope that is highly conserved in SARS-CoV and SARS-CoV-2. Crystallization studies of CR3022 bound to the SARS-CoV-2 spike protein have led to a structural model of its RBD epitope. The antibody can also detect SARS-CoV-2 in serological ELISAs.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    Azide free
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Tian, Li, Huang, Xia, Lu, Shi, Lu, Jiang, Yang, Wu, Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." in: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, 2020 (PubMed).

    Amanat, Stadlbauer, Strohmeier, Nguyen, Chromikova, McMahon, Jiang, Asthagiri-Arunkumar, Jurczyszak, Polanco, Bermudez-Gonzalez, Kleiner, Aydillo, Miorin, Fierer, Amarilis Lugo, Milunka Kojic, Stoever, Liu, Cunningham-Rundles, Felgner, Caplivski, Garcia-S: "A serological assay to detect SARS-CoV-2 seroconversion in humans" in: bioRxiv, 2020

    Amanat, Stadlbauer, Strohmeier, Nguyen, Chromikova, McMahon, Jiang, Asthagiri-Arunkumar, Jurczyszak, Polanco, Bermudez-Gonzalez, Kleiner, Aydillo, Miorin, Fierer, Amarilis Lugo, Milunka Kojic, Stoever, Liu, Cunningham-Rundles, Felgner, Caplivski, Garcia-S: "A serological assay to detect SARS-CoV-2 seroconversion in humans" in: bioRxiv, 2020

    Xiaolong Tian, Cheng Li, Ailing Huang, Shuai Xia, Sicong Lu, Zhengli Shi, Lu Lu, Shibo Jiang, Zhenlin Yang, Yanling Wu, Tianlei Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." in: bioRxiv, 2020

    Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier, Arunkumar, Tan, Bhavsar, Capuano, Kirkpatrick, Meade, Brito, Teo, McMahon, Simon, Krammer: "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." in: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, 2020 (PubMed).

    Yuan, Wu, Zhu, Lee, So, Lv, Mok, Wilson: "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." in: Science (New York, N.Y.), 2020 (PubMed).

    Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco, Peter, Guarino, Spreafico, Cameroni, Case, Chen, Havenar-Daughton, Snell, Telenti, Virgin, Lanzavecchia, Diamond et al.: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody." in: Nature, 2020 (PubMed).

    ter Meulen, van den Brink, Poon, Marissen, Leung, Cox, Cheung, Bakker, Bogaards, van Deventer, Preiser, Doerr, Chow, de Kruif, Peiris, Goudsmit: "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." in: PLoS medicine, Vol. 3, Issue 7, pp. e237, 2007 (PubMed).

  • Target
    Hintergrund
    Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
    UniProt
    P59594
  • Sie sind hier: